1 report

  • BUSINESS SEGMENTATION BY REVENUE

It has also signed a contract worth $## billion with Modern Pharmaceuticals for its messenger RNA therapeutics platform for developing new antiviral vaccines and passive immunity therapies.

  • Antiviral
  • Market Segment
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson